Class-action securities suit goes forward against Amgen

A U.S. appeals court will let Amgen ($AMGN) investors keep their class-action status in a complaint accusing the company of failing to fully disclose potential safety problems with its anemia drugs Epogen and Aranesp. The shareholder that originally filed the suit also alleges Amgen promoted significant off-label use of the drugs. Report